

---

Please share this newsletter with your colleagues and visit [www.HTRS.org](http://www.HTRS.org) for the latest announcements and opportunities! Email [HTRS@versiti.org](mailto:HTRS@versiti.org).

---



## HTRS Quarterly Newsletter

**Summer 2021**

---

Welcome to the re-launch of our HTRS quarterly newsletter, where you will find the latest HTRS news, updates, deadlines, and links – delivered right to your inbox! In this issue, learn about these current initiatives:

- *Annual Business Meeting June 14th: Register today!*
- *HTRS 2021 Wrap-Up and Enduring Materials Access*
- *Awards Programs News*
- *HTRS Institute*
- *Mentor Match Program*
- *Fellows and ConECCTOR Networks Updates*
- *Upcoming Meetings*
- *Key Partner Links*
- *HTRS Member Spotlight: 20 Questions with Bryce Kerlin, MD*



## 'Name the Newsletter' Contest!

**Inspired with an idea? Submit by June 11, 2021**

We are seeking a compelling name for our revamped Quarterly Newsletter for HTRS members. Submit ideas to [jziegler@versiti.org](mailto:jziegler@versiti.org) by Friday, June 11. HTRS board members will make the final selections.

*The winning entry will receive a \$50 Door Dash coupon!*

---

## HTRS Annual Business Meeting: June 14, 2021

**To register, [CLICK HERE](#)**

Our 2021 HTRS Annual Business Meeting will take place virtually on Monday, June 14, 2021 from 5:00–5:45 PM ET / 4:00–4:45 PM CT / 3:00–3:45 PM MT / 2:00–2:45 PM PT. The 45-minute meeting is open to all HTRS members.

**The first 50 members who register to attend will receive a special “HTRS Swag Box” post-meeting!**

This year’s meeting will focus on “The State of the Society.” HTRS Officers and Program Chairs will provide updates on outcomes of the virtual meetings offered this past year, including our HTRS 2021 Scientific Symposium, Research Colloquium, Trainee Workshops, and Fellows Network and ConECCTOR Network meetings. We will also introduce our incoming Directors, acknowledge outgoing Directors, present the annual Treasurer’s Report, hear the latest awards program news, and introduce new initiatives such as the HTRS Institute and an exciting new look for the Society.

The meeting will be hosted in Zoom Webinar. For instructions on joining and participating in a webinar, [CLICK HERE](#).

***HTRS Board Members: This meeting replaces the June 2021 Board call. The next regularly scheduled Board meeting will be **Monday, September 13, 2021.*****

---

# HTRS 2021 Scientific Symposium: It's a wrap!

## Enduring Materials Available through March 14, 2022

Thanks to all presenters, planning committee members, moderators, attendees, and industry supporters, our first-ever virtual HTRS 2021 Scientific Symposium was a success! *(See a complete list of our generous supporters later in this newsletter.)*

The Planning Committee's goal for this pandemic-year Symposium and its various pre-conference events was to ensure that the lively scientific exchange attendees have come to expect from HTRS events would continue online.

HTRS 2021 centered on hot topics in hemostasis and thrombosis, including COVID-19 and its impact on caring for patients with blood disorders. The meeting offered new and expanded opportunities for early-stage physician-scientists and researchers to engage with others in the field through interactive breakouts, mentoring opportunities, and face-to-face virtual networking events.

## HTRS 2021: Statistics

- 514 registered attendees (65% HTRS members)
- 54 accepted abstracts: 29 Hemostasis, 16 Thrombosis, 9 both H and T
- 17 abstract awardees
- 17 esteemed meeting sponsors and supporters
- 7 independent medical education grant providers

## Symposium Highlights

- **HTRS Research Colloquium** (March 8-9, 2021) – Professional education, access to experienced mentors, and career development guidance to junior faculty/junior attendings and post-doc students launching research careers in hemostasis and thrombosis
- **FWGBD Colloquium on Uterine Hemostasis** (March 9, 2021) – Leading faculty/researchers/clinicians to review the current understanding of the science and evidence-based practice related to the diagnosis and clinical management of abnormal uterine hemostasis
- **HTRS Trainee Workshop** (March 9, 2021) – A unique opportunity for 30 MDs or DOs in training (residents or fellows) interested in building careers in our field to meet, learn, and interact with leading experts in the field
- **HTRS Multidisciplinary Pre-Conference** (March 10-11, 2021) – A

diverse lineup of healthcare providers discussing the latest advances in treating patients with hemostatic and thrombotic disorders

- **HTRS Scientific Symposium** (March 10-12, 2021) –The culmination of a week of virtual programming for all career levels, this comprehensive scientific meeting was dedicated to continuing medical education and the advancement of clinical, translational, and basic science research related to non-malignant blood disorders in both pediatric and adult medicine
- **HTRS/Genentech “Best of HTRS 2021” Virtual Networking Events** – highlighting the presenters of abstracts honored with the Abstract Award (oral) and Abstract of Distinction (poster) at “virtual tables,” discussing their work in more detail with attendees outside of a formal presentation
- For their hard work in planning and implementing a major meeting, special thanks to HTRS 2021 Planning Committee Chair Jordan A. Shavit, MD, PhD (University of Michigan), Vice Chair Ayesha N. Zia, MD (UT Southwestern), and the entire Planning Committee, including Gowthami Arepally, MD (Duke University), Alan Mast, MD, PhD (Versiti Blood Research Institute) Suman Sood, MD, MS (University of Michigan), Alisa S. Wolberg, PhD (University of North Carolina at Chapel Hill), Loren D’Angelo, RN-BC, BSN, MSN, CPNP (Boston Children’s Hospital), Mary Lesh, PNP, MSN (University of California San Francisco), and Caitlin Montcrieff, CPNP, CPHON (Rhode Island Hospital).

## **HTRS 2021 Enduring Materials Available through March 14, 2022**

### **Original and New Registrants: See Specifics**

Jointly provided by HTRS and Postgraduate Institute for Medicine ([PIM](#)), the HTRS 2021 Scientific Symposium Enduring Materials will be available for one year post-conference for continuing medical accreditation.

Available Credits per Category: Physicians 14.5 credits, nurses 14.5 credits, APRNs 3.50 credits, pharmacists 14.50 credits

**Original HTRS 2021 Registrants/Attendees:** To receive open access to enduring materials, [CLICK HERE](#) and log in to the HTRS 2021 Meeting Site. Use the email address you used to register for HTRS 2021 (or the username provided to you by HTRS). If you need assistance or have further questions about logging in, email [contact@htrs2021.org](mailto:contact@htrs2021.org).

**New Registrants:** To register, [CLICK HERE](#) or [HERE](#). Check the HTRS [Members-Only](#) page on our website for your discount code. Access info will be provided after you register and pay.

For more info, [CLICK HERE](#).

*The [2021 HTRS Research Colloquium](#) was supported by sponsorships and grants from **Spark Therapeutics, Inc.**, **Pfizer Inc.**, and **The Hemophilia Alliance**.*

*The 2020 [HTRS Trainee Workshops](#) were supported by education grants from **Novo Nordisk Inc.**, **Takeda**, **CSL Behring**, and **Grifols**.*

***Many thanks to our sponsors and supporters!***

SANOFI GENZYME 

**Genentech**  
*A Member of the Roche Group*

**CSL Behring**  
Biotherapies for Life®





ново нордиск®



# GRIFOLS





# Instrumentation Laboratory

A Werfen Company



# THE HEMOPHILIA ALLIANCE

---

## HTRS Awards Program Updates

### HTRS Mentored Research Awards

*The 2021 [HTRS Mentored Research Awards](#) are supported by independent medical educational grants from Takeda (two awards) and CSL Behring (one award)*

*This February, these recipients were selected for three available awards*

- [Marisol Betensky, MD](#), Assistant Professor of Pediatrics, Johns Hopkins University School of Medicine, for her project: “Identification of Markers of Coagulation and Inflammation as Prognostic Factors for the Development of Recurrent Venous Thromboembolism (VTE) and Post-Thrombotic Syndrome in Children with Provoked VTE” (Mentors: **Neil A. Goldenberg, MD, PhD**, and **Ernest Amankwah, PhD**) – Takeda
- [Deirdre Nolfi Donegan, MD](#), Assistant Professor, University of

Pittsburgh, for her project: “Pathologic Platelet Activation in Sickle Cell Disease” (Mentors: **Cheryl Hillery, PhD**, and **Sruti Shiva, PhD**) – Takeda

- **Karen Zimowski, MD**, Assistant Professor, Emory University/Children’s Healthcare of Atlanta, for her project: “Cis-Acting Splicing Regulatory Elements in F5 Exon 13” (Mentors: **Christopher B. Doering, PhD**, and **Shannon L. Meeks, MD**) – CSL Behring

The grant period is July 1, 2021 through June 30, 2023. Many thanks to MRA Program Chair **Veronica Flood, MD**, Vice Chair **Neil Zakai, MD**, and the 32-member HTRS Scientific Review Committee.

For further info about the HTRS MRA Program, [CLICK HERE](#)

### **HTRS/Novo Nordisk Clinical Fellowship Award in Hemophilia and Rare Bleeding Disorders**

*The 2021 [HTRS/Novo Nordisk Clinical Fellowship Award in Hemophilia and Rare Bleeding Disorders](#) is supported by an educational grant from founding supporter **Novo Nordisk Inc.***

Many thanks to Program Chair **Stacy Croteau, MD, MS**, and our 5-member HTRS Scientific Review Committee. This program is in its final stages of completion and the grant period will begin July 1, 2021.

This spring, a decision was made to rename this award the “HTRS/Novo Nordisk Clinical Scholar Award in Hemophilia and Rare Bleeding Disorders” in order to expand the program's reach moving forward.

For further info about the HTRS CFA/CSA Program, [CLICK HERE](#)

### **HTRS/ATHN Dataset Research Engagement and ATHN Mentorship ("DREAM") Award**

*The 2021 [DREAM Award](#) is a collaboration of HTRS and ATHN and is supported by an independent medical education grant from Takeda.*

Our collaboration with ATHN continues with Mike Recht, MD, PhD, MBA at the helm at ATHN and HTRS Program Chairs Sarah O'Brien, MD (outgoing in 2021) and Allison Wheeler, MD (incoming in 2021 for a two-year term).

Earlier this year, the Scientific Review Committee selected two recipients for

the 2020 DREAM Award:

- [Angela Weyand, MD](#), Assistant Professor, University of Michigan Medical School for her project: “Pediatric Antiphospholipid Syndrome: A National Registry” (Mentor: Steven Pipe, MD) – Two-Year Grant Period of March 15, 2021 to March 14, 2023
- [Neeraja Swaminathan, MBBS](#), Fellow, University of Iowa Hospitals and Clinics for her project: “Elucidating the Age-Dependent Variation of Clinical and Laboratory Phenotype of Hemophilia Carriers Along with Prescription Trends of Hemostatic Therapies - Analysis of the ATHN Dataset” (Mentors: Anjali Sharathkumar, MD, MS, and Peter Kouides, MD) – One-Year Grant Period of March 15, 2021 to March 14, 2022

For more info about the DREAM Award, [CLICK HERE](#)

### **HTRS Mid-Career Research Award (MCRA)**

*The 2021 [HTRS Mid-Career Research Award \(MCRA\)](#) is supported by an education grant from Genentech, Inc.*

This spring, HTRS received Letters of Intent for the 2021 HTRS Mid-Career Research Award (MCRA). Seven applicants were invited to submit Full Proposals by July 26, 2021. The recipient of the 2021 MCRA will be announced in November 2021.

The MCRA program is chaired by **Shannon Meeks, MD**, and **Jill Johnsen, MD**, both of whom are past recipients of the award. The MCRA provides financial support for mid-career investigators pursuing full research independence and conducting clinical, translational, or basic science research in hemostasis and/or thrombosis. The project funded by this program will run for two years: November 2021 to October 2023.

For more info about the MCRA program, [CLICK HERE](#)

### **HTRS Student Research Awards (SRA)**

The 2021 [Student Research Awards \(SRA\)](#) Program is led by Program Chair **Alisa Wolberg, PhD**. HTRS is pleased to announce the four recent recipients of the 2021 HTRS Student Research Awards:

- **Cameron Barton**, a medical student at Oklahoma State University College of Osteopathic Medicine (Mentor: Joshua Muia, PhD at OSU). Project title: “Validation of a novel ADAMTS13 assay for

- characterization of patients with thrombotic thrombocytopenic purpura.”
- **Madelaine Duarte**, a medical student at Campbell University School of Ostopathic Medicine (Mentor: **Grace Lee, MD**, at Duke University Medical Center). Project title: “Neutrophil activation responses to platelet factor 4/heparin immune complexes.”
  - **Amelia Wilhelm**, an incoming student in the University of Washington Medical Scientist Training Program (Mentor: **Lindsey George, MD**, at Children’s Hospital of Philadelphia). Project title: “Mechanisms of FVIIIa inactivation.”
  - **Elie York**, an undergraduate student at Emory University (Mentor: **Glaivy Batsuli, MD**, at Emory University). Project title: “Investigating the role of IgMs in the immune response to factor VIII.”

For more info about the SRA program, [CLICK HERE](#)

---

---

## HTRS Institute

### Educational Workshops, Roundtable Discussions for Pharma Companies and HTRS-Partner Organizations

An exciting new program is in the works: our soon-to-be-launched HTRS Institute, whereby HTRS member colleagues in the hemostasis and thrombosis are available to travel to pharmaceutical companies and other HTRS-partner organizations to present educational workshops or participate in scientific roundtable discussions with HTRS industry partners.

We began piloting this opportunity to HTRS Corporate Colleagues this March at the HTRS 2021 Scientific Symposium, and momentum is gathering as we further develop this opportunity moving forward. Take advantage of the wealth of experience in clinical, basic, and translational science our HTRS members offer! Stay tuned for the roll-out of this program at our Annual Business Meeting on Monday, June 14, 2021.

For more info, email [HTRS@versiti.org](mailto:HTRS@versiti.org)

---

---

# HTRS Mentor Match Program: Career Development

## Opportunity for Fellows and ConECCTOR Networks

A new partnership now exists between the HTRS Fellows Network and ConECCTOR called the HTRS Mentor Match Program. Members of these networks now have an excellent opportunity to interact as mentors and mentees, further supporting this important time in their career development.

**Still want to take part but didn't sign up yet? Add your info to the following GOOGLE FORMS** and when you do, email [jziegler@versiti.org](mailto:jziegler@versiti.org) for a list of potential mentors, mentees, their specialties, and mentorship availability:

- Members of ConECCTOR: To become a mentor, [CLICK HERE](#)
- Members of Fellows Network: To become a mentee, [CLICK HERE](#)

Once you receive the list of potential mentors and mentees, review and identify someone with your similar availability/needs/specialty based on these three types of mentorships:

- **LIMITED INTERACTION:** Email contact with ConECCTOR members for brief questions
- **ONGOING MENTORSHIP:** Specific details TBD by Mentor/mentee (1 hour/month suggested, setting goals/milestones throughout the year)
- **ONE-TIME INTERACTION:** "Speed-Mentoring" event at a future conference (in-person/virtual)

Go ahead and reach out, and once you have established a partnership, let us know to make it official. If you already have a Mentor Match, we would appreciate brief testimonials on the positive value of your mentor/mentee experience so far. If you'd like to share, please email [htrs@versiti.org](mailto:htrs@versiti.org).

For more info, [CLICK HERE](#)

---

---

# HTRS Fellows Network and ConECCTOR Network Updates

The vibrant interaction between these two networks continued this spring as HTRS hosted a combined event on March 30, 2021 including a Virtual Fellows Network Webinar, Mentor Match interactive session, and ConECCTOR Meeting:

- The Fellows Network Webinar, “Applying for your First Faculty Position,” featured HTRS member panelists **Emily Ayers, MD, Glaivy Batsuli, MD, Ang Li, MD, MS, and Sven Olson, MD**. There were 31 attendees.
- Mentor Match Program – ConECCTOR and Fellows Network initiated three mentor/mentee matches during this session, with participants offered 30 minutes to connect virtually and get to know each other.
- The ConECCTOR Meeting featured presentations from Faculty Members **Nigel Key, MD, Robert Sidonio, Jr., MD, and Leslie Raffini, MD, MSCE**. There were 26 attendees.

For more info about this event, [CLICK HERE](#)

In addition, a Virtual ConECCTOR Grant Review Workshop on May 18, 2021 engaged Faculty Members **Margaret Ragni, MD, MPH, and Courtney Thornburg, MD**, as one participant received direct feedback for potential improvements to a current project/application that is being readied for NIH submission.

Many thanks to the leadership of our 2020-2022 ConECCTOR and Fellows Networks, including ConECCTOR Co-Chairs **Lauren Amos, MD, and Hope Pritchett Wilson, MD**, and Fellows Network Chair **Jennifer Yui, MD, MS**, along with Fellows Network Council Members **Anna Parks, MD, George Goshua, MD, Sherwin DeSouza, MD, Harry Feuntes Bayne, MD, Rudi-Ann Graham, MD, and Hana Lim, MD**.

For more info, [CLICK HERE](#)

*The [HTRS Junior Faculty Network, Consortium of Early Career Clinical, Translational and Outcomes Researchers \(ConECCTOR\)](#) is sponsored by **Spark Therapeutics, Inc.***

---

## SAVE THE DATE: Upcoming Meetings

- - [ISTH 2021 Virtual Congress](#): July 17-21, 2021
  - [ASH 2021](#) Hybrid Meeting: December 11-14, 2021, Atlanta, GA
  - [National Hemophilia Foundation/State of the Science 2021](#): September 12-15, 2021
  - [THNSA 2022](#) Hybrid Meeting: March 2022, Chicago, IL
  - HTRS 2023: March 10-12, 2023, Renaissance Orlando at Sea World, Orlando, FL (*details to come*)
- 
- 

## HTRS Partner Links

[National Hemophilia Foundation](#)

[FWGBD](#)

[National Institutes of Health](#)

[ISTH](#)

[THNSA](#)

---

---

# HTRS Member Spotlight

## 20 Questions Interview with Bryce Kerlin, MD

Professor of Pediatrics/Hematology, The Ohio State University College of Medicine Center

PI, Center for Clinical & Translational Research/The Abigail Wexner Research Institute, Nationwide Children's Hospital



### Getting to Know You

**1) Did you have a nickname while growing up? If yes, what was it and the story behind it?**

Andy. My middle name is Andrew, so it's kind of obvious. But only my grandfathers, father, and his best friend called me "Andy." Nostalgically, we named our first son Andrew so he could go by Andy. When he was about 3 years old, I called him Andy and he looked at me and said very definitively, "My name is Andrew." We don't call him Andy anymore.

**2) What was your favorite activity or hobby while growing up?**

Watersports. My grandparents had a small lake cottage in northern Indiana where we wiled away our summer swimming, fishing, waterskiing, tubing, etc.

**3) What interests do you pursue in your free time now?**

I still love being on or near the water. We live near a large reservoir just north of Columbus in Ohio. We are active members of our local sailing club on Alum Creek Lake where we dock our sailboat, a Precision 23 called "Sanity." If you don't find us at home or on the boat, then we will probably be traveling.

**4) If you could bring one book to a desert island, what would it be and why?**

JRR Tolkien's *Lord of the Rings*. I hope I get to bring all three parts of the trilogy.

**5) If you could bring one movie?**

Caddyshack. It is a comedic masterpiece. At one point in high school the cross-country team, including yours truly, had the whole movie memorized and would take parts and recite it for laughs.

**6) If you could live in another time or era, which one would you choose and why?**

The 1860s in the USA. The history buff in me is fascinated by the Civil War era. The war was gruesome and cruel, so my interest is not in being directly involved in the fighting, but rather better understanding the politics of the time.

**7) If you could invite four people, living or dead, for dinner at your house, who would they be and why?**

Abraham Lincoln, Ulysses Grant, Thomas Jefferson, and Benjamin Franklin. The first two are obvious based on my last answer. I would be interested in the opinions of both the founding fathers and the Civil War era notables on the evolution of our nation into what it has become. The state of (ongoing) racism in our nation and the stalemate (and dysfunction) of our Congress would be interesting discussion topics. What would they propose to fix these issues or may have written differently into our Constitution to avoid these outcomes?

**8) What place in the world would you like to visit for the first time?**

Greece – I want to sail the islands at a leisurely pace for about a month.

**9) Pretend you have decided not to pursue a career in medicine. What alternate career path would you choose?**

I would probably be a mechanic. My father ran a lawnmower repair service out of our garage. I paid my way through college fixing small engines in that shop and haven't paid for much engine service in my adult life. Ironically, getting that hands-on experience with how mechanical pieces and parts fit and worked together turned out to be formative to my research career because I think it taught me how to develop a mental picture of the way in which various biological molecules fit and work together in four dimensions.

**10) A genie in a bottle gives you three wishes. What would you wish?**

I would first wish for a cure for sickle cell disease, I hope we're getting closer to that. The more experience I gain as a hematologist, the more I realize just how devastating this disease is and I often wonder how many potentially great minds and influencers humanity has lost to it over the years. My second wish would be for our nation to reinvest in science and healthcare policy. It made us great once and set us apart from the rest of the world, it can do so again, but our leaders must embrace it to overcome the scientific denialism and conspiracy beliefs that are running rampant. My third wish would be for unlimited wishes, obviously.

## **Your Brilliant Career**

### **1) Who were the mentors who inspired you to choose non-malignant hematology as a career?**

I pursued Clinical Laboratory Science in my undergraduate studies and spent a year working in a community hospital laboratory before going to medical school. I most enjoyed the hematology and blood bank sections of the lab and went away to medical school thinking I wanted to become a hematopathologist. I had a bit of an identification crisis when I realized that I didn't enjoy my pathology rotation in the least. The "moment" came several months later while working with Dr. Joan Cox Gill in the pediatric hematology clinic as a third-year medical student. We saw a child in her clinic for anemia and as I presented the case we went across the hall to look at his blood smear. I remember sitting down to the double-headed microscope and she began to teach me how to look at a peripheral smear, like I'm sure she had a thousand times before. When we got to the red blood cell portion, I said something to the effect of "Well, wouldn't it be all those spherocytes that are the problem?" I'll never forget how she looked up at me over the top of the scope and asked what my background was. We made the presumptive diagnosis of hereditary spherocytosis and went back to discuss the diagnosis and plan with the family. It was the perfect blend of what I had already learned and how I could both expand upon it and apply it as a physician. I was fortunate to later train as a fellow under Dr. Gill's capable tutelage as well as Drs. Bob Montgomery, Paul Scott, Cheryl Hillery, and other classical pediatric hematology luminaries in Milwaukee.

### **2) What do you enjoy most about your career today?**

Trainees. I really enjoy nurturing and watching them have their own "a-ha" moments when they discover something new or realize how the bigger puzzle fits together for the first time.

**3) What do you enjoy least about your career today?**

Two things, really. Firstly, meetings, meetings, and more meetings. The only thing a meeting is good for is acquiring new work. Meanwhile, there are so many meetings that you rarely seem to have time to just do the work. The second is the electronic medical record. Turning physicians into data entry technicians really has taken all the joy out of the practice of clinical medicine.

**4) Describe a highlight of your career to date.**

I was fortunate to work on fruitful basic science projects as a fellow in Dr. Hartmut Weiler's highly productive lab. We made novel observations about the role of factor V Leiden and hyperfibrinogenemia in inflammation. Our work on factor V Leiden was very exciting and the most interesting part was recognition that heterozygosity was protective, but homozygosity was not. This work led to a plenary paper in *Blood* and several years later, after I was no longer working on the project, the team had the number 1 abstract at ASH explaining the underlying mechanisms.

**5) What scientific or clinical publication in your field has been most influential to your clinical practice and/or research?**

My clinical practice is focused on pediatric thrombosis treatment and management, so the anticoagulation guideline publications are a very important resource. It would help, of course, if we had more high-level data in pediatrics that we could rely upon in lieu of extrapolations from the adult data. With the recent completion of Einstein Jr, it looks like we may finally be headed in that direction. Scientifically, my lab's study of thrombin signaling in glomerular disease has most been influenced by a *Blood* paper examining the effects of coagulation activation on diabetic nephropathy, published in 2011 by my friend and colleague, Berend Isermann's lab.

**6) Which of your research studies or publications are you most proud of?**

My lab has spent the past several years trying to understand the role of coagulation enzyme signaling in glomerular disease – a leading cause of kidney failure. Because the glomerulus is the kidney's primary filter unit that retains plasma proteins in the vasculature but allows waste products through, glomerular disease often causes massive urinary losses of plasma proteins, including coagulation factors. We have spent the last several years trying to understand the consequences of pathological urinary coagulation factor activity. Our most

important and exciting discovery thus far is that urinary (pro)thrombin drives injury of glomerular cells called podocytes. In fact, we have now been able to show that we can dramatically reduce the signs and symptoms of glomerular disease in animal models by antagonizing (pro)thrombin, including with the use of direct oral anticoagulants. Our initial observations were published in the *Journal of the American Society of Nephrology* and much of the remaining work has been presented at society meetings and will (hopefully) soon be published.

**7) What assay do you find the most problematic to do and/or interpret for patients?**

Platelet aggregometry. Every lab does this assay differently, it is highly sensitive to pre-analytic variables, and interpretation is messy. Much work has been done by Dr. Hayward and her NASCOLA colleagues to standardize both the assay and its interpretation, but it seems like implementation of these standards at most labs continues to be less than desirable.

**8) What has changed in medicine for the better and for the worse since you completed your training?**

The continued emphasis on maximizing the business of medicine by both insurers and hospitals has significantly hampered the delivery of best care. Meanwhile, our improved understanding of the molecular mechanisms of disease have enabled better and better therapies that are both specific and more effective than previous approaches.

**9) What do you predict will be the next major advancement in your field?**

The next major advancement in thrombosis management will likely come from an improved understanding of the molecular and cellular vascular biology of post-thrombotic syndrome. The ATTRACT and SOX trials have demonstrated that early thrombus clearance and augmented venous pressure, respectively, either have no influence or a minor influence on ultimate venous function after DVT. What we really need to understand is the response of the vessel wall components in order to unravel the mechanisms that drive dysfunction and vs. recovery so that we can develop therapeutics targeting the desirable responses. Ultimately, we hematologists will need to embrace vascular and extravascular biology to fully understand the basis of this and other long-term sequelae of thrombosis.

**10) What words of guidance would you give fellows contemplating a**

## **career in non-malignant hematology?**

Follow your passion. Then, identify a niche that no one else is working on actively and cultivate that niche as your area of expertise and research.

Questions? Feel free to email us at [HTRS@Versiti.org](mailto:HTRS@Versiti.org).

Hemostasis and Thrombosis Research Society

Quarterly Newsletter

Milwaukee, WI 53266-3548

(414) 937-6569 | [htrs@versiti.org](mailto:htrs@versiti.org) | [htrs.org](http://htrs.org)